VANI Stock — Vivani Medical Inc.

Vivani Medical Inc. (VANI)

Updated October 16, 2026.

VANI is a Stock. Total return is -99.8% over the past 11.9 years, 453.7 points behind SPY at 353.9%.

Vivani Medical is a clinical-stage biopharmaceutical company developing miniaturized subdermal drug implants using its NanoPortal technology to treat chronic diseases, with a pipeline focused on weight management and diabetes treatments in humans, plus a veterinary obesity and diabetes candidate. The company does not currently distribute to shareholders. Vivani Medical appeals to growth-oriented investors with risk tolerance for early-stage biotech development, as it remains pre-commercialization with no established revenue stream.

VANI performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.8% over the past 11.9 years, 453.7 points behind SPY at 353.9%. Over the past year its total return — price change plus distributions reinvested — is -24.3%. Its deepest 1-year drawdown was 49.8%.

VANI key facts

Asset type

Stock

Asset class

Equity

Inception date

11/19/2014

Distribution frequency

None

Last close

$1.12 (as of 2026-10-16)

Market cap

$101,027,759

Average volume

361575.0

Payment date

01/06/2020

Beta

3.303

Payout ratio

0.0%

EPS

$-0.36

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VANI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 49.8%.

Who may consider VANI — and who may not

It is a weaker fit for investors who need monthly cash flow (VANI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on VANI

• All tickers starting with V

Tagged: Healthcare.

Frequently asked questions